Phase I Study of Single-Agent Utomilumab (PF-05082566), a 4-1BB/CD137 Agonist, in Patients with Advanced Cancer

H. Segal, Neil; Ruth He, Aiwu; Doi, Toshihiko; Levy, Ronald; Bhatia, Shailender; J. Pishvaian, Michael; Cesari, Rossano; Chen, Ying; B. Davis, Craig; Huang, Bo; D. Thall, Aron; K. Gopal, Ajay

doi:10.1158/1078-0432.ccr-17-1922

Public

Phase I Study of Single-Agent Utomilumab (PF-05082566), a 4-1BB/CD137 Agonist, in Patients with Advanced Cancer

Published in Clinical Cancer Research • Mar 16, 2018

Authors:

Neil H. Segal

Aiwu Ruth He

Toshihiko Doi

Abstract

Abstract Purpose: Utomilumab (PF-05082566) is an agonistic mAb that engages the immune costimulatory molecule 4-1BB/CD137. In this first-in-human, phase I, open-label, multicenter, multiple-dose study (NCT01307267) we evaluated safety, tolerability, pharmacokinetics, preliminary clinical activity, a...

Subject

Medicine

Tolerability

Rash

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!